http://www.elsevierbi.com/search?type=Deals&advanced=%20(%40industries%3d%22Medical%20Devices%22)Medical Device Deals from Elsevier Business Intelligenceen-usCopyright © 2012 Elsevier Inc. All rights reserved. Elsevier Business Intelligence, www.ElsevierBI.com.http://www.elsevierbi.com/deals/199610196http://www.elsevierbi.com/deals/199610196?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Conceptus] (minimally invasive surgical products for the female reproductive system) has bought [Microgyn], a privately-held company developing products used in hysterectomy procedures, in a combined stock/cash transaction. Microgyn filed a 510k application last June for its lead product, the {Continuous-flow Isotonic Solution System} which allows the use of isotonic or physiologic fluids during hysteroscopic procedures (a less invasive form of hysterectomy) as opposed to the currently-used hypotonic fluids. Hypotonic fluids can cause serious complications if they are absorbed. Conceptus, which is concentrating on developing surgical products for fallopian tube disorders, said it is acquiringMicrogyn to broaden its product line.Fri, 01 Nov 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610183http://www.elsevierbi.com/deals/199610183?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Respironics] (hospital and home respiratory products) acquired [Lifecare] (Colorado-based maker of portable ventilation therapy products) for $50mm. Lifecare had sales of $33.1mm last year, one-fourth of those sales from international markets. It has an office in Munich, Germany with a staff of 35, which will add to Respironic's European base. Respironics said Lifecare's products,which hold the world's leading market share in the portable volume ventilator category, are a good fit with its line of non-invasive ventilatory support products. Lifecare's products include the {PLV-100} and {PLV-102} ventilators, used for patient life support, and also a line of portable oxygen concentrators. The former president of Lifecare, Geoffrey Waters, will service as VP, Customer Satisfaction of Respironics.Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610203http://www.elsevierbi.com/deals/199610203?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Johnson & Johnson]'s [Ethicon Endo-Surgery] has acquired [Indigo Medical], a private company in Palo Alto that markets diode laser systems for urological use. Indigo's non-invasive laser is marketed in Europe for treating benign prostatic hyperplasia and awaits FDA approval for that indication (it is already sold in the US for general urology). J&J had been an investor in Indigo since helping finance the company's founding in 1990.Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620515http://www.elsevierbi.com/deals/199620515?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Baxter Healthcare]'s [Nextran] (organ transplant technology) division will collaborate with [Cytel] (immunotherapeutics) to develop a carbohydrate column for xenotransplantation (animal organs transplanted into humans). Nextran funding will consist of an upfront payment including an equity investment and milestones. Cytel will exclusively supply its enzymatic sugar nucleotide cycling technology (SNC) (permits mass production of bioactive carbohydrates) for Nextran to incorporate into its xenotransplant product; a column that filters the organ recipient's blood to remove carbohydrate-attacking antibodies that would cause organ rejection. Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620517http://www.elsevierbi.com/deals/199620517?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[DePuy] (orthopedics manufacturers) will exclusively distribute in the US and Canada, [Haemonetics]'{CollectFirst} automatic blood processing system. Haemonetics will be responsible for manufacturing the product and distributing it outside the US and Canada. The {CollectFirst} system, FDA-approved in 1995, enables continual collection, filtration and reinfusion of recycled blood. Haemonetics develops systems for blood processing that focus on the following markets: surgical blood salvaging, blood component therapy, red cell and plasma collection.Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630284http://www.elsevierbi.com/deals/199630284?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Xomed Surgical Products] (ear, nose, and throat) netted nearly $49mm in its initial public offering of 2.5mm shares at $21 per share, which was the high end of its anticipated $19-21 price range. Xomed will use the proceeds to repay its $21mm term loan and to redeem shares of its series C preferred stock from existing stockowners; redemption will reduce the position of principal owner Warburg Pincus Investors to 48% from 78%. The company's ENT surgical products include powered tissue-removal systems, other microendoscopy instruments, implantable devices, nerve monitoring systems, and disposable fluid-control products. Xomed describes itself as the only major provider of surgical products with a direct sales force exclusively serving the ENT surgeon.Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630350http://www.elsevierbi.com/deals/199630350?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Premier Laser Systems] (lasers and fiber optic systems for niche dental, ophthalmic, and surgical applications) raised net proceeds of $11.7mm in a follow-on offering of 12,650 units, including the overallotment, at $1000 per unit. This offering replaces a $25mm common share offering Premier registered in May but withdrew. Each unit consisted of 140 class A common shares and 95 class B warrants (each exchangeable till 11/99 for a class A common share for $8). Proceeds will fund expansion of marketing and distribution, including international marketing, and new products. Premier makes minimally invasive lasers and disposable fiber optic delivery systems, typically compact and transportable, for use in the in-office and surgicenter markets. Premier has filed for or received FDA clearance for various lasers used in teeth whitening, gum surgery, urology, dermatology, podiatry, ophthalmology, and tissue melding as an alternative to sutures.Tue, 01 Oct 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610186http://www.elsevierbi.com/deals/199610186?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Physician Sales & Service] Inc. (large distributor of supplies, equipment, and medicines to office-based doctors) will acquire [Diagnostic Imaging Inc.] (radiology and imaging distributor) for total consideration of just over $19mm. PSS will give common stock valued at $13mm and assume $6.2mm of DII's debt. DII reported revenues of $58mm for 1996 but was losing money. The company distributes radiology and imaging equipment, chemicals, and supplies, and provides technical service to the acute and alternate site markets through 13 locations in five states. PSS said it plans to be aggressive in acquiring other firms in DII's niche; the radiology and imaging sector is worth over $4bn and is served now by o450 distributors. Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610195http://www.elsevierbi.com/deals/199610195?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Nellcor Puritan Bennett] (respiratory devices) has bought [Aequitron] (electronic respiratory products and devices that aid the physically handicapped) in a stock swap valued at about $61mm. The exchange ratio is 0.432 Nellcor common share for each Aequitron share, subject to change based on Nellcor's price prior to closing and subject to a maximum of 0.440. Nellcor wants to add what it believes to be the leading portable ventilators in the market to its own ventilator products, after which it will have the broadest line in the industry. Aequitron, which had sales last year of $38.5mm, makes ventilators for both home and hospital use, as well as wheelchair lifts and automobile hand controls for people with mobility challenges. Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620465http://www.elsevierbi.com/deals/199620465?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[J&J]'s [Cordis] subsidiary will fund development of [LocalMed]'s {StentaSleeve} stent delivery system meant for use with the Cordis {Palmaz-Schatz} coronary stent. The deal includes an exclusive licensing and supply agreement. LocalMed, a private interventional cardiology company formed four years ago by MDs and a scientist, has developed a technology platform for transforming standard angioplasty balloon catheters into systems that can deliver stents and drug delivery catheters for treatment of coronary artery disease. Mounted with {Palmaz-Schatz} stents, the {StentaSleeve} device tracks over a standard PTCA balloon catheter, shuttling stents to the lesions; the same balloon that has been used for lesion dilatation also deploys the stents. LocalMed also uses the over-the-balloon technology in its marketed {InfusaSleeve} drug delivery catheter. Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620479http://www.elsevierbi.com/deals/199620479?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Medeva PLC] subsidiary, [Medeva Pharmaceuticals] has granted an exclusive license to [Bristol-Myers Squibb]'s multi-source generic pharmaceutical division [Apothecon] to market its albuterol metered dose inhaler (MDI) in the US. Medeva will manufacture and supply for Apothecon the FDA-approved MDI, a generic albuterol (formulation of bronchodilator, salbutamol) inhaler for treating asthma. The MDI will enter a market with an estimated worth of more than $800mma year. Apothecon has over $350mm in annual sales.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620459http://www.elsevierbi.com/deals/199620459?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Molecular Technologies Inc.], the DNA detection and diagnostics arm of [Silicon MicroDevices Inc.], licensed exclusive worldwide rights to a DNA fragment sizing technology from [Los Alamos National Laboratory]. The technology, the fruit of a 1993 development agreement between MTI and Los Alamos, sorts and sizes DNA fragments via laser induced fluorescence. It is said to be faster, more accurate, and more quantitative than current electrophoretic methods, especially for larger fragments (up to 200 kbp). The technology is covered by a 6/95 US patent filing entitled Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620489http://www.elsevierbi.com/deals/199620489?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[PolyMedica Industries] (specialized health care products) signed an exclusive distribution agreement with Japan's [Kuraray Co.] to market PolyMedica's {Mitraflex} polymer-based wound dressings in Japan. Kuraray will be responsible for obtaining approval for the product under the Japanese Health Insurance Reimbursement System. Once approved, Kuraray will pay license fees to PolyMedica. {Mitraflex} wound care dressings are highly flexible and have the moisture vapor transport capacity of thin film dressings. Moist healing promotes faster healing with less scarring than traditional cotton and gauze.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620493http://www.elsevierbi.com/deals/199620493?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[BioTransplant] (anti-rejection drugs and organ transplant systems) acquired exclusive worldwide rights, in the field of organ transplantation, to use [Activated Cell Therapy]'s bone marrow stem cell isolation device. BT will use ACT's bone marrow purification devices to process and isolate human and porcine bone marrow cells for its {AlloMune} system, for human-to-human solid organ transplantation, and {XenoMune} system, for pig-to-human organ transplantation. The systems promote transplant tolerance by re-educating the recipient's immune system to accept the donor organ. ACT's device recently received FDA approval.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620498http://www.elsevierbi.com/deals/199620498?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[VWR Scientific Products] (supplier of lab equipment and chemicals) signed a five-year distribution agreement with [Alpha Pro Tech] (disposable protective apparel) worth approximately $25mm to APT. In exchange for exclusive worldwide rights to market APT's product line of medical and clean room protective wear, VWR must purchase at least $5mm of APT's products annually for five years. VWR, which has a worldwide network of over 130,000 customers, will supply APT's lines of face masks, eye shields and protective apparel to the pharmaceutical, biotech, chemical and electronic industries.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620499http://www.elsevierbi.com/deals/199620499?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Oncology Systems Group] of [Siemens Medical] formed an alliance to distribute and service [Intraop Medical]'s cancer treatment system, {Mobetron}, in the US, Europe, Latin American, Russia, Australia and most of Asia. Intraop's {Mobetron} is a mobile, self-shielded electron beam system designed for treating cancer using intraoperative radiotherapy, which is the direct application of radiation to a tumor and/or tumor bed while a patient is undergoing surgery.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620501http://www.elsevierbi.com/deals/199620501?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Perkin-Elmer] has signed an exclusive agreement to license [LXR Biotechnology]'s scanning laser digital imaging (SLDI) technology initially for use in hybridization-based assays but which include broader applications. PE will have exclusive worldwide rights and will pay LXR royalties on the sale of equipment based on the technology. SLDI can provide the foundation for new products which can rapidly image fluorescent-tagged biomolecules over a wide surface, such as a microscope slide. The technology was originally developed at Ohio State University and licensed to Optical Analytic which LXR acquired in 1993. PE may explore applying SLDI to clinical diagnostic instrumentation.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630231http://www.elsevierbi.com/deals/199630231?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Nitinol Medical Technologies] (minimally invasive medical devices) has completed its IPO of 3mm common shares at $11 per share, netting $30.69mm. Nitinol had expected the share price to be between $12 and $14. Nitinol will use the proceeds for redemption of its redeemable preferred stock; for R&D, clinical trials and regulatory matters; development of marketing and sales capabilities; and for other corporate purposes. Nitinol's products includea line of patented self-expanding nitinol stents, a patented nitinol vena cava filter designed to prevent pulmonary embolism, and a soon-to-be-marketed patented septal occluder for the minimally invasive repair of defects in theseptal wall of the heart.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630313http://www.elsevierbi.com/deals/199630313?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[RayMedica Inc.] (founded in 1990; developing an alternative treatment to spinal fusion) raised $5 million in its second round of private financing. Investment bank Miller, Johnson & Kuehn managed the equity placement. About 120,000 patients a year suffer from lumbar disc problems which require spinal fusion, a procedure which limits mobility of the spine. RayMedica's {Prosthetic Disc Nucleus} is implanted between two vertebrae to restore normal disc space. Pilot studies have been conducted in Germany.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630382http://www.elsevierbi.com/deals/199630382?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Baxter] has spun off its large supplies and distribution subsidiary [Allegiance Corp.] by distributing to shareholders one Allegiance share for each Baxter share held. Analysts predict that Allegiance will trade at $13-15. Allegiance had 1995 sales of $4.57bn and would have accounted for about 45% of Baxter's total sales this year on a consolidated basis. The unit has three main businesses: manufacture of low-end central supply items like gowns, trays, and wound drainage products; the {Shared Risk/Shared Savings} and {ValueLink} programs, which help hospitals reduce their supplies costs through efficient ordering and utilization; and a distribution operation that claims about 30% of the hospital supply market and 40% of the lab supply market. Allegiance has 60 distribution centers and 28 manufacturing plants and claims it can take care of up to 80% of a hospital's total supply needs.Sun, 01 Sep 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610163http://www.elsevierbi.com/deals/199610163?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Thermo Electron] has acquired patient monitoring systems manufacturer [Medical Data Electronics] for $37.5mm in cash. MDE, which offers a line of portable multiparameter monitors, telemetry monitors, and patient data simulators, had sales of $34mm in 1995.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610173http://www.elsevierbi.com/deals/199610173?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Bristol-Myers Squibb]'s orthopedic company, [Zimmer] has purchased from medical instruments maker, [The Anspach Effort], its craniofacial fracture management business segment, which makes tiny devices used mainly for fixation of bones in the head. The product line, formerly called {Anspach Fixation Systems} but now to be marketed in the US and abroad under the Zimmer name through its orthopedic implant division, includes micro-sized titanium plates and screws that are used in craniofacial/maxillofacial and neurological bone reconstruction. Zimmer already claims the industry's broadest offering in fracture management and has a sales force of 500. It says it hopes to expand the application of the small-size, low-profileAnspach devices to other trauma subspecialties that involve small bone fixation, such as hand and foot surgery.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610174http://www.elsevierbi.com/deals/199610174?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Medtronic] (implantable and invasive medical products) will buy the sensors business unit of [Draeger Medical Electronics], of the Netherlands. The unit offers two product lines, both compatible with external patient monitoring equipment. {Microtransducer} catheters are for neurological, cardiovascular or urodynamic applications. The {Ventcontrol MTC} is placed directly in the brai, allowing continual drainage of fluid and simultaneously monitoring intracranial pressure. Earlier this year, Medtronic bought [InStent] (makes self-expanding and balloon-expandable stents) and [AneuRx] (endovascular stented graft and itselivery system). Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610179http://www.elsevierbi.com/deals/199610179?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[CR Bard] will buy privately held [Impra] (vascular surgical product) in a $143mm cash transaction which is expected to close this quarter. Impra, which was founded in 1994, is located in Tempe, AZ and offers over 260 products to the vascular surgeon marketplace. Bard will consolidate its own vascular product line at the Tempe location. Through this acquisition, Bard will strethen its cardiovascular business, a key franchise for the company and currently a favorite in the market. The company said it was especially attracted to Impra's R&D efforts in vascular grafts and endovascular technology. Impra had FY1995 revenues of $49mm. Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610180http://www.elsevierbi.com/deals/199610180?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)In an effort to more strategically compete among intravenous infusion therapy product manufacturers, [Advanced Medical] will acquire [Ivac Medical Systems] for $400mm in cash and merge it with its subsidiary [Imed]. Advanced Medical will finance the acquisition and transaction costs through $315mm of bank debt, $125mm of subordinated notes and $40mm of common equity. Ivac's president and CEO will become president and CEO of Advanced Medical, and Advanced Medical's president will assume the position of EVP & CFO of the merged company. The companies will combine product lines and significantly increase their market share to approximately 40%, making them a viable competitor against the larger, more dominant players in infusion therapy and technology-based drug delivery devices, [Baxter] and [Abbott]. Ivac considered going public, but chose to sell the company. Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610184http://www.elsevierbi.com/deals/199610184?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[US Surgical] has bid $18 a share for the 12.6mm outstanding shares of endoscope manufacturer [Circon] in a hostile takeover attempt. The $18 price represents an 83% premium over the average Circon trading price for the 10 days preceding the offer. Though Circon has rejected the bid, US Surgical reported having gained control of 76% of the shares not owned by Circon management on Sept. 18. Circon posted revenues of $160.4mm for fiscal 1995. Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620419http://www.elsevierbi.com/deals/199620419?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[ResMed] (sleep disorder diagnostic devices) will co-develop [Local Silence]'s (Los Altos, CA-based device company) digital signal processing technology for diagnosing obstructive sleep apnea. The companies say the technology is suitable for unattended home monitoring. ResMed was formed in 1989, the result of a management buy-out of a project from the [Baxter Centre for Medical Research in Australia]. The company manufactures sleep disorder monitors and markets them worldwide under the {Sullivan} brand name (named for its inventor Professor Colin E. Sullivan of the University of Sydney). Obstructive sleep apnea, a breathing disorder accompanied by loud snoring and the cessation of breathing for up to 90 seconds, affects about 5% of the adult population, and has been linked to hypertension, stroke and heart disease.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620417http://www.elsevierbi.com/deals/199620417?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Big Sky Laser Technologies] (OEM medical laser manufacturer; also develops lasers for scientific, military, and industrial markets) and [Cell Robotics International] (laser-based medical and research equipment) are allying to develop new medical lasers. Using some of its patented technology, Cell Robotics will determine market applications and feasibility of products, develop prototypes, and handle FDA regulatory submissions. Big Sky is responsible for final product development and manufacturing. The agreement allows both companies to continue developing and manufacturing certain product lines independently. The first joint project will speed international introduction of Cell Robotics' {Lasette} laser finger perforator for nearly painless capillary blood sampling. Blue Sky pays for design enhancement and completion of pre-production prototypes; Cell Robotics takes care of marketing, hoping to launch the first commercial units in '97.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620420http://www.elsevierbi.com/deals/199620420?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Edap International SA] has granted [Boston Scientific] and its partner [Urologix] (MIS devices for urology) separate non-exclusive worldwide licenses to its intellecutal property in the field of microwave treatment of the prostate. The agreement will permit BS and Urologix to go ahead with their plans to market Urologix's {Thermo-Ablation Therapy} ({T3}) device for treating benign prostatic hyperplasia. In June, BS had licensed marketing rights outside the US and Japn for the {T3}, which is to be submitted for FDA approval later this year; but Edap's Cambridge, MA subsidiary had received approval for its {Prostatron} BPH device in May. Both {T3} and {Prostatron} treat the symptoms of an enlarged prostate non-surgically, using transurethral application of microwaves. The licensees will pay an initial license fee and make prepaid and ongoing royalty payments up to an agreed maximum.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620437http://www.elsevierbi.com/deals/199620437?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[HemoCleanse] (liver assist devices) will develop a bioartificial liver device utilizing [VivoRx]'s (biodegradable biocompatible materials for drug delivery) porcine liver cell product {HepatoRx} for the treatment of acute liver failure. HemoCleanse's novel liver-assist device {BioLogic-DT System} (510k clearance) uses absorbent chemicals to remove liver toxins while balancing blood chemistries. Its second generation device {BioLogic-DTPFC} will feature an Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620443http://www.elsevierbi.com/deals/199620443?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Biomira] (diagnostics and therapeutics for cancer) has exclusively licensed worldwide rights to its monoclonal antibody, MAb-170, to [Neoprobe] for use in its {RIGS} technology for the surgical detection of breast cancer. The MAb is in Phase II/III trials now in BIOMF's {Tru-Scint} imaging agent for recurrent breast cancer; NEOP will conduct Phase I trials in patients undergoing breast-conserving surgery. NEOP will pay an upfront fee, milestones, and royalties upon commercialization of a MAb-170-incorporating {RIGS} product. BIOMF has granted NEOP an option to use the MAb in other indications, such as ovarian cancer, and an option on another BIOMF antibody, MAb-174. In NEOP's surgical procedure, the antibody is injected into the patient where it binds to cancerous tissue. The surgeon, using a handheld gamma-detecting probe, can identify and remove diseased tissue which might otherwise have gone undetected.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620505http://www.elsevierbi.com/deals/199620505?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Becton Dickinson] in an exclusive agreement will market [Specialized Health Products International]'s {Safety Cradle} sharps container line. SHPI will exclusively manufacture and supply the containers for BD. SHPI develops health care safety products to help prevent accidental needlesticks. Its {Safety Cradle} line allows for the safe disposal and transporting of contaminated sharps.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620497http://www.elsevierbi.com/deals/199620497?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cook] (surgical products) gets a worldwide exclusive license to [BCM]/[MD Anderson Cancer Center]'s technology for impregnating catheters and other implants with an antimicrobial agent; co-developed by BCM's Rabih Darouiche and MD Anderson's Issam Raad. Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630266http://www.elsevierbi.com/deals/199630266?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Sunrise Technologies] (dental and ophthalmic lasers) has netted $2.25mm through a Regulation D financing in which it sold 2.3mm shares. Proceeds will mainly be used to fund ongoing clinical development of the Sunrise Corneal Shaping System. Phase II trials of the procedure, which involves the shrinking of corneal collagen to treat mild hyperopia, are being conducted by Suntise subsidiary [Laser Biotech].Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630308http://www.elsevierbi.com/deals/199630308?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[HumaScan], a development stage company marketing a breast differential temperature sensor device, completed its initial public offering of 2.7mm shares of stock at $6 per share, raising net proceeds of approximately $14mm. HumaScan plans to use about $4mm of the proceeds to fund sales and marketing expenses, $2.5mm to fund additional clinical trials of its {BreastAlert} differential temperature sensor device, and remaining proceeds for licensing fees, inventory and general corporate purposes. The {BreastAlert} (510k clearance) is a device that indicates unusual heat patterns on a patient's breast which can alert the physician of potential tumor growth. The device is a non-invasive, adjunctiverimary care physicians. HumaScan acquired rights to the technology from [Scantek] in July 1995 and has entered into an exclusive distribution agreement with [Physician Sales & Service].Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630296http://www.elsevierbi.com/deals/199630296?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cambridge Heart] (non-invasive cardiovascular diagnosis) has netted $20.4mm in its IPO of 2.4mm shares at $9 per share. Selling shareholders sold an additional 62,250 shares. The net proceeds of the offering will be used for research and clinical development, manufacturing scale-up, and sales and marketing activities. The company's lead product, {CH 2000}, is a cardiac stress test system that, as well as performing conventional stress tests, can measure T-wave alternans ( ECG patterns associated with sudden cardiac dealth) down to one millionth of a volt. [Medtronic], which agreed to conduct a joint clinical study using CHI's system to evaluate its implantable defibrillator, invested $3.5mm in the IPO.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630320http://www.elsevierbi.com/deals/199630320?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Sterile Recoveries] (reusable gowns, towels, drapes and disposable products) completed its initial public offering of 2mm shares, raising net proceeds of $17.67mm The company plans to use about $11.1mm of the proceeds to repay indebtedness associated with the acquisition of [AMSCO], and the remaining proceeds for working capital and the purchase of more reusable surgical products and equipment. Sterile Recoveries delivers drapes and other reusable products used for surgery to hospitals, then retrieves and sterilizes them. The company serves over 200 hospitals and surgery centers in seventeen states.Thu, 01 Aug 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610159http://www.elsevierbi.com/deals/199610159?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[OrthoLogic] (products to heal musculoskeletal tissues) signed a binding letter of intent to acquire [Sutter Corp.] (distributes orthopedic rehab products) from [Columbia/HCA Healthcare] for about $25mm cash. The managed care company had acquired Sutter in 1990 in a merger transaction. OrthoLogic and Sutter both market directly to orthopedic surgeons; together they will have a sales force of over 150. Sutter, which had 1995 revenues of about $30mm, has a specialty in continuous passive motion rehabilitation devices. OrthoLogic recently received an FDA warning letter regarding its marketing practices for its lead product, a bone growth stimulator; its other products address spinalfusion and fracture fixation. Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610162http://www.elsevierbi.com/deals/199610162?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Positron] will buy [GE Medical Systems]' positron emission tomography (PET) development and production operations, including its cyclotron division based in Sweden, for $25mm cash plus 10% of Positron's common stock. The stock would be worth about $4-5mm at its current trading price of about $3.75 per share. GEMS also gets a three-year option to buy another 15%. Through a purchase and distribution agreement, Positron will make and both companies will distribute the GEMS {Advance} and {Quest} PET products. The addition of the large GEMS sales force will help establish Positron in international markets. GEMS will continue to provide service and application support to its installed base andto future PET installations. PET technology, in use for two decades, indicates chemical changes in the body related to metabolism, as well as producing structural images; it is used for early detection of cancer and for certain cardiology and neurology applications. GEMS's PET machines offer the high resolution advantageous in neurology and oncology. Its other modalities in diagnostic imaging are x-ray, MRI, CT, ultrasound, and nuclear imaging. Positron's focus is its {Posicam} line of PET devices, which provide the rapid imaging needed in cardiology. Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610150http://www.elsevierbi.com/deals/199610150?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Protocol Systems] (patient monitoring) acquired all the equity of [Pryon Corp.] (capnography equipment) for 1.3mm shares of common stock (about 5.65 Protocol shares for each Pryon share), worth about $26.7mm at Protocol's current $20.50 trading price. Capnographs measure carbon dioxide concentration in a patient's respiratory gases, an early indication of circulatory, pulmonary, or metabolic distress. The deal gives the buyer new technology plus helps position it as a provider of OEM technologies for medical device makers--Pryon's sells its devices mainly to OEM customers such as [Nellcor Puritan Bennett], [Spacelabs], and [Marquette], which package them in their own instrumentation. Protocol's sales organization is also distributing the new subsidiary's standalone capnographs worldwide. Key Pryon personnel will stay on after the merger, and engineering, manufacturing, and OEM sales operations will continue at the Pryon facility as before.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610167http://www.elsevierbi.com/deals/199610167?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Essilor of America] (glass and plastic optical lenses and anti-reflective coatings; subsidiary of Paris-based [Essilor International]) has acquired [Duffens Optical] of Topeka, KS, which operates 12 optical labs in midwestern and south central states. Duffens, which has about 550 employees, has long been a distributor of the EOA {Varilux} lens; it will still market Essilor and non-Essilor lenses; the company will retain its identity and continue business at its existing locations. One of its executives will join EOA as VP of marketing. Through acquisitions, EOA is building a network of optical labs; during 1996 it also bought [Omega Group] (Dallas), [Southern Optical] (Greensboro, NC), and [WOS Inc.] (Green Bay). (Source:EOA press release)Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620327http://www.elsevierbi.com/deals/199620327?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Medtronic] (cardiovascular devices) and [Regeneron Pharmaceuticals] (compounds to treat neurodegenerative diseases) signed an agreement to develop therapeutics using experimental Regeneron compounds and Medtronic's delivery device. The initial candidate is Regeneron's {Axokine} for the treatment of Huntington's disease. Regeneron will direct preclinical development of the drug and retain manufacturing and marketing rights to the drug. Medtronic retains rights to manufacture and market the drug delivery device {SynchroMed}. Medtronic will make milestone payments and receive royalties on sales of any drug developed; Medtronic has also made an upfront equity investment of (uf)$10mm (460,500 common shares at $21.72 per share, a (pr)40% premium to the prior day's stock price) in Regeneron. With its equity investment, Medtronic also received a 5-year warrant to purchase an additional 107,400 Regeneron shares at an exercise price of $21.72 per share.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620338http://www.elsevierbi.com/deals/199620338?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cooper Surgical] (gynecological products) and [Ximed Medical Systems] (suction, irrigation, electrosurgical instruments) agreed that Cooper Surgical will market worldwide Ximed's electrovaporization products for the treatment of gynecological disorders. The electrovaporization products--new roller bars, roller loops, and cutting loops-- are used to vaporize soft tissue growth instead of conventional resection, resulting in minimal blood loss. Vaporization eliminates the need to remove tissue fragments that occur with conventional cutting loops and improves visibility at the operative site. The product also incorporates a proprietary non-stick material to minimize tissue adhering to the product. These products can be usedin place of hysterectomies to treat many cases of fibroids and abnormal bleeding in the uterus.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620342http://www.elsevierbi.com/deals/199620342?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Collagen Corp.] (injectable bovine collagen products) has agreed to market worldwide [Tissue Technologies Inc.]'s (San Francisco) tube-shaped implant for deep facial wrinkles and scars, made from expanded polyetraflouroethylene (ePTFE). Collagen paid an upfront fee and will buy the product wholesale from TT. The agreement includes an exclusive technology license TT had obtained from the Univ. of CA. The device will be launched this fall by Collagen's [Appearance Technologies Division], with subsequent launches internationally as regulatory approvals are obtained. The implant is intended to be used in soft tissue augmentation in sub-dermal lesions, such a nasolabial wrinkles, for which injectiable collagen products provide less-than-optimal results. The tubular implant received marketing clearance from the FDA in April 1996.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620344http://www.elsevierbi.com/deals/199620344?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Xytronyx] (periodontal tests) has purchased an exclusive worldwide license to [Wound Healing of Oklahoma]'s (laser technology) {Laser/Sensitizer Assisted Immunotherapy} technology. Xytronyx plans to initially target breast cancer with the {LSAI} therapy, although it is expected the {LSAI} will be useful with other cancers. The technology involves injecting a tumor with an infrared absorbing dye and an immunoadjuvant,owed by treatment with an infrared laser. Like photodynamic therapy, LSAI is designed to destroy tissue in the tumor, but it is also intended to trigger an immune reaction in the patient to complete the destruction of the primary tumor andto destroy metastatic tumors.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620355http://www.elsevierbi.com/deals/199620355?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Norland Medical Systems] (x-ray bone densitometers) acquired exclusive worldwide rights to future bone diagnostic devices developed by [Vitel] (ultrasound critical angle reflection technology) (UCRT) using Vitel's proprietary technology. Norland has made an equity investment in Vitel as part of this agreement. Vitel has rights to UCRT under a worldwide exclusive license from the [University of Texas] system. UCRT does not use radiation, an advantage over x-ray testing, and provides quantitative assessment of bone quality, permitting assessment of both cortical and trabecular bone. Norland states that the UCRT will complement its x-ray based technologies.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620326http://www.elsevierbi.com/deals/199620326?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Minntech Corp.] (dialysis and reprocessing products) will market [Gambro]'s [Cobe Laboratories]'(oxygenator systems) oxygenator devices that fall within the scope of three Cobe patents. The products covered by the patents include an oxygenator, a reservoir, a sampling device, and oxygenator systems. Cobe will now focus on the manufacture and marketing of its new {Biocor} oxygenator and future oxygenator systems. Minntech's core technologies are used in dialysis, reprocessing and sterilants, cardiosurgery and water purification.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620358http://www.elsevierbi.com/deals/199620358?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Sherwood-Davis & Geck] and [Mead Johnson Nutritionals] agreed to develop and market enteral nutritional formula products and devices in the US. SD&G will be the sales agent for MJN nutritionals in the alternate site health care market, including nursing homes and home health care agencies; it will sell MJN's products alongside its own enteral access devices. SD&G and MJN will cooperatively market medical nutritionals and enteral devices in the acute care/hospital market. MJN will continue to market its medical nutritionals in the retail market independently of the agreement. The agreement provides the two companies with a means of offering a complete range of products for contract purchasing.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620340http://www.elsevierbi.com/deals/199620340?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Corange]'s [Boehringer Mannheim] and [MiniMed] (external and implantable insulin pumps) have agreed to jointly promote each other's related diabetes care products in the US. The two companies will create a joint sales and marketing council to develop strategies and material to be used in promoting the products. BM produces glucose meters and test strips; MiniMed produces external infusion systems for diabetes management. MiniMed also plans to begin clinical trials of a minimally invasive subcutaneous glucose monitor in late 1996. For the past fiscal year, MiniMed had sales of $45mm, 95% of which were generated by external pumps and disposables. Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620376http://www.elsevierbi.com/deals/199620376?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Boston Scientific Corp.] (interventional medical devices) and [Urologix] (MIS products for urological disorders) agreed that BS will market Urologix's {Transurethral Thermo-ablation Therapy (T3)} worldwide except for the US and Japan. The T3 product is used to treat benign prostatic hyperplasia. Clinical trials have been completed in Britain and were to be presented at the British Association of Urological Surgeons meeting in Scotland at the end of June. Urologix anticipates submitting a PMA in the US for the T3 later in 1996. [Nihon Kohden Corp.] has exclusive marketing rights to the product in Japan, where an application for marketing approval is pending.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620385http://www.elsevierbi.com/deals/199620385?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Research Medical] (Midvale, UT; cardiovascular surgery devices) exclusively licensed a peripheral limb reperfusion kit from vascular surgeon Dr. Paul Walker, and Alex Romaschin, PhD, of [The Toronto Hospital], paying only royalties. Licensed directly from the doctors, the kit consists of a line of balloon-tipped reperfusion catheters and special solutions to flush ischemic limbs free of toxic metabolites. Toxins accumulate in oxygen deprived muscle tissue of patients undergoing embolectomies, peripheral vascular grafting, abdominal aortic aneurysm repair, and other vascular procedures that compromise blood flow. Toxin build-up is linked to tissue death and complications such as kidney failure, heart attacks, and lung failure. RMED pays for Phase I trials under Walker at The Toronto Hospital and one other site. RMED filed patents on the delivery and recovery aspects of the kit, which hasn't yet been tested in humans, as well as the specialized solutions.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620401http://www.elsevierbi.com/deals/199620401?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[FemRx] (interventional surgery devices) and [Stryker Endoscopy] (endoscopic camera systems; a subsidiary of surgical device and implantables maker [Stryker Corp.]) have agreed to help promote each other's gynecology products. FemRx makes the {OperaStar} and {Flo-Stat} surgical systems used in an endometrial resection/ablation procedure, an alternative treatment less invasive than hysterectomy, for patients with abnormal menstrual bleeding. Surgeons perform FemRx's procedures under direct visualization on a video monitor, and FemRx will now promote Stryker's gynecologic endoscopy cameras by featuring them in all their doctor training programs and trade shows. Stryker, in return, will give sales leads to the FemRx sales organization.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620412http://www.elsevierbi.com/deals/199620412?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Mallinckrodt] licensed North and South American rights to [Conceptus Inc.]'s (minimally invasive access to female reproductive system) fallopian tube catheterization system for the hospital market. The devices are used in fluoroscopic diagnosis of fallopian tube disease, a major cause of infertility. Conceptus will continue marketing the catheterization system to interventional gynecologists. The agreement will give it the benefit ofMallinckrodt's standing with radiologists and its national contracts and connections in managed care. A subsidiary of [Schering AG] is marketing some Conceptus fallopian diagnosis and treatment devices in the UK. Conceptus is also developing a nonsurgical system to perform fallopian tube sterilization.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620404http://www.elsevierbi.com/deals/199620404?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Fischer Imaging] (x-ray imaging systems and related devices) licensed exclusive marketing rights in the US radiology market for the {Performa} breast ultrasound system made by [Dornier Medical Systems]' [Acoustic Imaging] unit. Leveraging its direct sales force, Fischer will sell {Performa} in conjunction with its own {Mammotest} stereotactic core needle breast biopsy system and other x-ray imaging products, encouraging doctors to use the complementary products to perform real time, in-office biopsies under ultrasound guidance. Acoustic's own sales force will also continue to market the {Performa}. The two companies have worked together before; Fischer supplies x-ray imaging systems that are incorporated into the Dornier lithotripter that was just approved by the FDA.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630235http://www.elsevierbi.com/deals/199630235?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[ESC Medical Systems], an Israeli company that makes pulsed light devices for noninvasive treatment of benign vascular lesions, raised net proceeds of $17.6mm in a follow-on offering of 750,000 common shares at $24.75 per share. Selling shareholders dominated the financing, placing 3,050,000 additional shares. The company had gone public in January at $15 per share. ESC has US clearance for its {PhotoDerm VL} device for leg veins and other lesions; it filed 2/96 for FDA approval of {PhotoDerm PL} for pigmented lesions such as tattoos, and plans to file this year for two general dermatology and skin resurfacing lasers; a hair removal system is in advanced clinicals; and the {VersaLight} device that treats skin cancers with a continuous wave light source is at the preclinical stage. ESC has already commercialized all of those products outside the US.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630265http://www.elsevierbi.com/deals/199630265?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Positron Corp.] (PET imaging devices), a publicly traded company, raised $1,250,000 through a private offering of units, priced at $50 each, consisting of 25,000 shares of 8% convertible preferred stock plus warrants to purchase 100,000 common shares. Each share of the series B stock is initially convertible into 26 common shares; each warrant is exercisable for one common share at an exercise price of $2 per share. The underlying shares have not yet been registered; further, conversionand exercise must wait until the shareholders approve authorization of additional shares. Positron makes and markets positron emission tomography devices branded {Posicam}; these systems are used for diagnosing and managing heart disease and certain neurological illness and cancers.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630278http://www.elsevierbi.com/deals/199630278?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Angeion] (products to treat and cure arrhythmias) raised net proceeds of approximately $27.5mm from a follow-on offering of 4.2mm shares of common stock at $7 per share. The company will use about $12mm of the proceeds for R&D, $3.6mm to expand marketing activities, $2.5mm to scale-up manufacturing facilities, $0.7mm to fund clinical trials, and remaining proceeds for general corporate purposes. Angeion isdeveloping the {Sentinel} series of implantable cardioverter defibrillators designed to treat abnormally rapid heartbeats. The {Sentinel} series of defibrillators are smaller and lighter than current ones on the market and offer a longer device life. Angeion also develops catheter-based ablation systems to treat abnormally rapid heartbeats.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630349http://www.elsevierbi.com/deals/199630349?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)Publicly-traded [MBf USA] (examination gloves and condoms) raised $2.4mm in a private placement of its class B common stock. The company's majority shareholder, MBf International bought 488,953 shares for $1.4mm, a 15% discount to market; its Indonesian glove manufacturing partner [PIE Health care] bought 296,296 for $1mm at market price. MBf USA markets the {Glovetex} brand of medical examination gloves and {Playboy} condoms.Mon, 01 Jul 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610137http://www.elsevierbi.com/deals/199610137?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Pfizer] agreed to acquire [Vesta Medical Inc.] of Mountain View, CA for its proprietary system for treating menorrhagia (abnormal menstrual bleeding). About a million women worldwide seek treatment yearly for the condition, which can disrupt normal activities and cause chronic anemia. Conventional therapy is performed under general anesthesia in an operating room and often requires hysterectomy (surgical removal of the uterus). The {VestaBlate} system is a less invasive method that uses only local anesthesia and is a doctor's office procedure. It involves catheter insertion, through the vagina, of an inflatable balloon that carries electrodes on its surface to electrosurgically remove just the endometrial tissue in the uterine lining. Vesta got IDE approval last fall to begin clinical trials. Pfizer's [Valleylab] unit, which specializes in systems that use radio-frequency energy to create and cauterize incisions, will take over manufacturing and marketing of Vesta's products.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610141http://www.elsevierbi.com/deals/199610141?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Target Therapeutics] (MIS devices for neurological disorders) will acquire privately held [Interventional Therapeutics], a developer of vascular occlusion devices for neurovascular embolization, for an undisclosed amount of stock. IT's products include detachable silicon balloons used in treating fistulas and {Contour} embolization particulates. The transaction is being treated as a purchase, and Target will take a charge of over $10mm in its first quarter to account for it. According to Target's 1996 10K, the company closed the acquisition on 5/23/96 and swapped 331,000 Target shares of all of Interventional's outstanding shares. Target closed at $45.75 that day. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610166http://www.elsevierbi.com/deals/199610166?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[DeRoyal Industries] (manufacturer of a variety of medical supplies, equipment, and devices) acquired the assets of [Lamedco], whose main product lines are umbilical cord clamps and footprint systems for baby identification. Both companies are in the Knoxville, TN area. The Lamedco products will move to DeRoyal's critical care division. DeRoyal now offers about 30 neonatal care products. In business for over 20 years, it manufactures varied health care products such as unitized delivery systems, surgical accessories, orthopedic softgoods, orthotics, wound dressing, and computer software for hospitals.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620260http://www.elsevierbi.com/deals/199620260?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Medi-Ject] (needle-free drug delivery system) and [Teva Pharmaceutical Industries] (ethical pharmaceuticals) have entered into an agreement under which Medi-Ject will develop a customized needle-free drug delivery system for Teva's use. Teva will use the product with {Copaxone}, its investigational product for the treatment of relapsing multiple sclerosis. A needle-free delivery method would be a boon to sufferers of MS, who must inject the drug on a daily basis. If cleared for marketing by the FDA, {Copaxone} will then be marketed in the US by [Teva Marion Partners] of Missouri, a partnership established between Teva and [Hoechst Marion Roussel].Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620284http://www.elsevierbi.com/deals/199620284?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Candela Corp.] (formerly Candela Laser Corp.; lasers for urology and dermatology) licensed exclusive commercialization rights in dermatology and plastic surgery to a dynamic cooling device from the [University of California, Irvine]. The device is incorporated into the hand piece of a dermatological laser, and sprays a cryogen onto the skin immediately preceeding the laser pulse. By selectively cooling the top layers of skin, the device is meant to reduce thermal injurypain without affecting treatment efficacy. Candela pays royalties and milestones for rights to the issued patent covering the device, which was developed at UC Irvine's [Beckman Laser Institute and Medical Clinic]. Candela pays annualfees as a corporate affiliate of the Institute, and so paid no upfront license fee. Candela will sponsor an ongoing development program at the Institute for the technology, although regulatory approval is expected by 8/96.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620298http://www.elsevierbi.com/deals/199620298?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Schering AG]'s UK subsidiary [Schering Health Care Ltd.] will market [Conceptus]' line of devices for the diagnosis and treatment of infertility in the UK. The product line includes Conceptus' {Transcervical Tubal Access Catheter System} and the {Transcervical Falloposcopy System} for the endoscopic diagnosis and treatment of fallopian tube disorders. Schering, the leading supplier of oral contraceptives and diagnostic imaging agents in the UK, recently introduced {Echovist}, a contrast agent for fallopian tube disorders.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620287http://www.elsevierbi.com/deals/199620287?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[HemaSure] entered a five-year collaboration with the [American Red Cross Biomedical Services] to develop new blood filters and pathogen inactivation systems. HemaSure has exclusive rights to commercialize any products resulting from the collaboration. The ARC and HemaSure will both contribute technology and manpower to the effort which aims at developing an array of new products including filters for in-line red blood cells, whole blood, platelets, red cell pheresis, tumor cells and cryopreservatives. The ARC, which controls some 45% of the US market for blood products, will receive royalties on sales. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620308http://www.elsevierbi.com/deals/199620308?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Collagen] (injectable collagen) licensed marketing rights to [Biomatrix]'s (viscoelastic products) {Hylaform} hylan gel in Europe, Japan, Australia, Canada and markets in Latin America and the Middle East for $5mm and royalties. Biomatrix also granted Collagen rights to market {Hylaform} in the US for an additional payment once FDA market clearance for the product is obtained. Collagen plans to market the product to dermatologists, plastic surgeons and other aesthetic medical specialists. Collagen will pay royalties to Biomatrix based on potential incremental growth of the dermal augmentation business as well as sales of its own dermal augmentation products. Biomatrix also internationally markets {Synvisc} for the treatment of osteoarthritis of the knee, and {Hylashield} to protect the surface of the eye from dry and damaging environmental substances. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620310http://www.elsevierbi.com/deals/199620310?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Bio-Vascular] (cardiac and vascular surgery products) and [Mentor Corp.] (medical/surgical devices) agreed to collaborate on testing and bringing to market Bio-Vascular's {Bio-Sling} product for use in the surgical treatment of stress incontinence. Bio-Vascular will be responsible for research and development, manufacturing and regulatory affairs. Mentor will be responsible for worldwide surgical training, marketing, and distribution. The agreement is intended to be multi-year, although this will be determined after a mini-clinical trial that begins this month of the {Bio-Sling}, a new product in Bio-Vascular's {Tissue-Guard} product line. Currently, surgery is used to take tissue from elsewhere on the patient's body and create a sling that lifts the bladder neck and supports the urethra. The {Bio-Sling} is made from processed bovine pericardium tissue, replacing the need for taking tissue from the patient.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620317http://www.elsevierbi.com/deals/199620317?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Vital Signs] will help market [Utah Medical Products]' {Deltran IV} disposable pressure transducer (used to monitor blood pressure in the critical care setting) in the US. {Deltran IV} is an automated, lower cost version of the {Deltran II} pressure transducer, currently distributed by [Baxter] under the name {Uniflow}. Utah will continue to supply Baxter with {Deltran II}, though {Deltran IV} will exclusively be marketed by Utah, Vital Signs, and possibly a third partner. Utah estimates the total US disposable pressure transducer market at $100mm, in which Baxter holds a 30% market share with Utah's products.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620291http://www.elsevierbi.com/deals/199620291?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Organogenesis] (Canton, MA; tissue-engineering & cell therapy) and [Massachusetts General Hospital] will collaborate to develop an artificial liver assist device. Envisioned to expand hepatic capacity in liver failure patients, blood is pumped through the device and cleansed of toxins like ammonia by human hepatocytes, or liver cells, and returned to the patient. Organogenesis' expertise is in procuring and culturing cells while MGH collaborators Dr. Mehmet Toner and Dr. Martin Yarmush will contribute a background in liver biochemistry and device design. Terms of the sponsored research agreement were not released, but Organogenesis hasoptions (free of licensing fee) on any intellectual property generated through the collaboration. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620329http://www.elsevierbi.com/deals/199620329?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Fiat] subsidiary [Sorin Biomedica]'s Cardio division (cardiovascular equipment and surgical devices) has licensed the marketing and distribution rights outside the US for [Eclipse Surgical Technologies]'s transmyocardial revascularization products. Sorin, a large cardiovascular company that makes and sells such products as heart valves, vascular grafts, pacemakers, and oxygenators, agrees to buy at least 30 TMR laser systems before the end of 1997 and plans to develop a global marketfor them. Eclipse has already installed its system in over 33 US and 11 European hospitals; its laser is an investigational device now in Phase II clinical testing in patients with severe angina who are not candidates for traditional bypass surgery or balloon angioplasty. The TMR procedure uses a laser to create pathways into the heart chamber, traveling directly through heart muscle; the tiny openings are intended to alleviate symptoms of angina or chest pain.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620324http://www.elsevierbi.com/deals/199620324?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Olympus Optical] (medical imaging; claims a 70% share of the world market for endoscopic equipment) signed a letter of intent to exclusively market and distribute [Xillix Technologies]' {Life-Lung} endoscopy system worldwide. Xillix, based in British Columbia, specializes in its {Light Imaging Fluorescence Endoscopy} line of imaging devices for early detection of cancer. An FDA panel recently recommended granting marketing approval for {Life-Lung}. The new arrangement with Olympus expands the companies' earlier agreement, signed in August 1994, which called for joint development of Xillix's {Life-GI}, a system for early detection of cancer of the gastrointestinal tract (esophagus, stomach, and colon), and had given Olympus worldwide rights to the GI product and Japanese rights to {Life-Lung}. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620384http://www.elsevierbi.com/deals/199620384?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cheung Laboratories] (hyperthermia equipment for cancer and prostatic diseases) licensed exclusive commercialization rights for medical uses of the [Massachusetts Institute of Technology]'s Adaptive Phase Array (APA) technology. Originally developed by Dr. Alan Fenn and colleagues at MIT's [Lincoln Laboratory] for use in microwave radar systems, APA was adapted to Cheung's hyperthermia devices during a four-year collaboration. The company pays a license fee and royalties for exclusive rights to patents covering APA's use in cancer treatment systems, including a breast cancer system and a deep tumor-heating device for tumors in the brain, lung and liver. Hyperthermia is used to destroy tumors via microwave induced heating. APA technology improves current systems' limited ability to focus heat energy. Cheung will add APA to its {Microfocus 1000} microwave hyperthermia system.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630112http://www.elsevierbi.com/deals/199630112?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Positron] (PET imaging) netted $3.5mm from the private placement of 2,683,309 shares of Series A 8% convertible preferred stock and 1,341,907 warrants, including the overallotment. The preferred shares convert 1 for 1 to common stock, as do the warrants whose exercise price is $2 per share. Positron had to increase its tangible assets to maintain its listing on the NASDAQ National Market System. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630166http://www.elsevierbi.com/deals/199630166?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Fusion Medical Technologies] (developing closure products for use on surgical wounds caused in open and minimally invasive surgery) raised net proceeds of $25.4mm in its IPO of 2.1mm common shares at $13 per share. With the money, the company will fund clinical trials and R&D and expand its marketing and sales activities. Fusion filed a 510k marketing application in April for its first product, the {RapiSeal} bioresorbable collagen patch, for sealing air leaks caused during surgery for lung cancer and emphysema. In the past, such leaks have required venting through chest tubes. {RapiSeal} closes leaks on the suture and staple line, without perforating or stressing neighboring tissue. With the use of a radio frequency coagulation generator, the surgeon can apply energy that makes the patch also flow into the irregularities and fissures of the underlying tissue. Fusion is also developing liquid sealants that require no energy source.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630219http://www.elsevierbi.com/deals/199630219?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Vivus] (male impotence therapeutics) has completed a follow-on offering of 2mm shares at $26.75 per share, netting $49.8mm. Net proceeds of the offering will be used for marketing and sales, manufacturing scale-up, and general corporate purposes. The company's lead product, {MUSE}, is alprostadil delivered via a transurethal plastic applicator; an NDA was filedfor the product in March 1996.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630229http://www.elsevierbi.com/deals/199630229?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Del Global Technologies] (imaging equipment) raised net proceeds of $22.3mm in a follow-on offering of 2,275,000 common shares, including overallotment shares, at $10.50 per share. For several years the company has been its shifting its focus towards its medical imaging technologies and away from its non-medical businesses (electronics for high voltage products and noise suppression technology for industrial and defense uses); medical imaging currently accounts for about 66% of Del's sales. Product lines include mammography systems and general and dental x-ray equipment. The company wants to specialize in systems that cost less than $100,000 per unit. Del made export sales of about $12mm (of $24mm net sales) in fiscal 1995; these were direct sales of its products as well as sales of subsystems that are incorporated into OEM customers' products for export.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630232http://www.elsevierbi.com/deals/199630232?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)Eyeglass lens manufacturer [Sola International] has netted $54.6mm in a follow-on offering of 2,805,415 shares at 28.625 per share, in which Sola sold 2.02mm shares and selling shareholders sold 785,415 shares. The net proceeds of the offering will chiefly be used to repay debt incurred by its recent $107mm acquisition of [American Optical]. The financing values Sola at about $681.8mm; it posted revenues of $387.7mm for the fiscal year ended March 31, 1996.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630245http://www.elsevierbi.com/deals/199630245?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Imatron] (diagnostic imaging systems) completed a $16mm private placement for its subsidiary, [HeartScan Imaging], which provides coronary artery disease risk assessment services in centers using Imatron's proprietary {Ultrafast CT} technology. A group of institutional investors invested $16mm in exchange for 100,000 shares of HeartScan Imaging Series A preferred stock for 40% of HeartScan. The shares are exchangeable into 3.2mm shares of Imatron common stock for up to 2 years. HeartScan expects to begin a separate, stand alone, company within the next two years. The company plans to use the proceeds to open new diagnostic imaging centers.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630248http://www.elsevierbi.com/deals/199630248?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Imagyn] (micro-invasive devices for diagnosis and treatment of gynecological disorders) raised net proceeds of $37.5mm in its initial public offering of 2.75mm shares at $15 per share, above the $11-13 range filed in the preliminary prospectus. The company plans on using about $7mm of the proceeds to fund product introduction, sales and marketing, and to develop physician training programs. Another $5mm will be used for R&D, $1.5mm for capital equipment, and remaining proceeds for general corporate purposes. Imagyn's products include the {MicroLap} high resolution endoscope system, (510k clearance) for diagnosing pelvic inflammatory disease, endometriosis, and for infertility problems. Imagyn also markets its {Ovation} falloposcopy microhysteroscopy system for infertility. The company's micro-optics and micro-access devices allow physicians to access the abdominal cavity in a less-invasive procedure, without anesthesia and on an out-patient basis.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630255http://www.elsevierbi.com/deals/199630255?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cardiovascular Dynamics] (vascular catheters) has completed an IPO of 3.4mm shares of common stock, raising net proceeds of $37.94mm. CVD had been a division of [EndoSonics], which retains a 49% holding. Net proceeds will be used for product development, capital expenditures, clinical trials and studies, working capital, direct sales and marketing, and repayment of debt to [Endosonics.] The company, in addition to offering all shares granted an overallotment of 510,000 to its underwriters. CVD's catheters are used in conjunction with angioplasty and other interventional procedures such as vascular stenting and drug delivery. CVD has developed the {Focus and Multiple Microporous Membrane} technology, which allows physicians to deliver radial force, stents, contrast media or drugs to the treatment site, and the {SmartNeedle}, which uses Doppler ultrasound technology to provide access to the body's vascular system.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630257http://www.elsevierbi.com/deals/199630257?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Innovasive Devices], which develops open-surgical and minimally invasive tissue repair systems, completed its initial public offering of 1.9mm shares of common stock at $12.50 per share, raising net proceeds of approximately $21mm. The company plans to use the proceeds to fund R&D, to expand its marketing and sales efforts and manufacturing capacity, as well as for general corporate purposes. Innovasive's tissue repair systems are aimed at repairing soft tissue injuries. The company's initial products are the {Radial Osteo Compression (ROC)} suture fasteners and arthroscopic instruments marketed for use in the sports medicine segment of the orthopedic market. {ROC} suture fasteners, which use bioabsorbable and collagen-based biomaterial composites that dissolve or remodel into surrounding tissue, are inserted below the surface of the bone to hold soft tissue in place while it is healing.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630268http://www.elsevierbi.com/deals/199630268?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Fischer Imaging] (medical imaging equipment) raised $13.5mm in a follow-on offering of 1.35mm common shares at $12 per share. The company's newest products focus on imaging systems related to minimally invasive therapies, primarly diagnosis and treatment of breast cancer, heart disease and vascular disease. Products include {Mammotest} a less invasive needle biopsy system and {Senoscan}(currently in clincal trials) a digital mammography system to detect breast cancer in younger women, who have denser breast tissue. Fischer is also developing specialty imaging systems for electrophysiology and enendovascular procedures.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630263http://www.elsevierbi.com/deals/199630263?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[EP MedSystems] (device for internal cardioversion of atrial fibrillation) went public, raising $11.8mm from the sale of 2.5mm common shares at $5.50 per share. The company will use $1.5mm for clinical trials, $1.5mm for sales and marketing, and $1.5mm for manufacturing. The {ALERT} system, its lead product, uses a disposable electrode catheter to deliver low energy impulses directly to the insideof the heart to stop atrial fibrillation. It can be used on an outpatient basis without anesthesia. Current therapies involve a combination of high energy external cardioversion in conjunction with antiarrhythmic or anticoagulant drugs. EP MedSystems is in the process of filing an IDE application for the system. It also markets a line of electrophysiology products in the US through distributors. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630242http://www.elsevierbi.com/deals/199630242?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)Italian electromedical device maker [Esaote Biomedica] went public, raising gross proceeds of $50mm through the sale of 20mm shares (about 44% of its total equity) at $2.50 (Lit. 3900) per share. Esaote makes ultrasound and other diagnostic machines, primarily for use in cardiology and neurology. The company's subsidiaries in France, Germany, and the US enjoyed a 28% rise in sales from 1994 to 1995; overall 1995 sales were $165mm, 11.4% over the previous year. [Bracco] (also Italian; main business is diagnostic imaging agents) invested $11.5 to buy a 15% stake in Esaote in January.Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630319http://www.elsevierbi.com/deals/199630319?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Cardiac Pathways] (minimally invasive systems for diagnosis and treatment of cardiac tachyarrhythmias) raised $44.2mm. Cardiac Pathways is developing {Ventricular Tacycardia Ablation System} and {Arrhythmia Mapping System}. The products, which are in early clinical development, are aimed at the electrophysiology market.The company distributes its {Trio Ensemble} and {Radii} catheters through [Arrow] (medical products for critical care). Arrow has a $9.1mm equity investment in Cardiac Pathways and accounts for 37% of its sales. Proceeds will be used to fund R&D and clinical tricatheter-based mapping and ablation systems. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199630356http://www.elsevierbi.com/deals/199630356?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Norland Medical Systems] ( bone densiometry x-ray equipment for diagnosing osteoporosis) filed 1.5mm shares at an estimated a $20.75 per share, in a follow-on offering in which it hopes to raise $28.9mm. Norland will use proceeds for developing new products and sales and marketing programs, expanding manufacturing and for working capital and general corporate purposes. The company manufactures bone measurement diagnostics that apply three various technology methods: DXA technology which is a dual energy x-ray; SXA technology which is a single energy x-ray; and pQCT technology which is a peripheral three-dimensional x-ray. Sat, 01 Jun 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610554http://www.elsevierbi.com/deals/199610554?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Steris Corp.] (sterile processing systems) will merge with [Amsco International] (infection control products), issuing 0.46 Steris shares (14.7 million in total) for each Amsco share in a $660 million deal, based on Steris' Dec. 15 Nasdaq closing price. With the acquisition, Amsco President and CEO Richard Gilleland and Amsco director Russell Carson will join Steris' board of directors. The combined entity will have a sales and service force of over 1000 representatives in North America. Amsco posted revenues of $483 million for fiscal year 1994.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610047http://www.elsevierbi.com/deals/199610047?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Palomar Medical Technologies] (medical lasers) has acquired [Tissue Technologies] (cosmetic laser for removing face wrinkles) for 3mm Palomar shares valued at $34.5mm. TT already hasback orders for $20 million of its {Tru-Pulse} device, a CO2 laser system that has been approved for marketing. The {Tru-Pulse} sells for only $50,000, considerably less than other CO2 skin resurfacing lasers, so it should be attractive to doctors interesting in entering this area of cosmetic surgery. Now Palomar will be able to offer a complete range of cosmetic laser products: its ruby and copper vapor lasers are used for tattoo removal, skin lesion repair, and spider vein treatment. It also has developed a hair removal laser that is awaiting FDA 510k approval.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610113http://www.elsevierbi.com/deals/199610113?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Boston Scientific] (interventional medical devices) has purchased [MinTec] (stent technology) for approximately $70mm in cash. BS already has a relationship with MinTec; the two companies have been working on the development of a bifurcated stent graft and delivery system for the endovascular repair of abdominal aortic aneurysms. BS will combine MinTec's proprietary stent technology with Meadox Medical's expertise in vascular grafts (BS purchased Meadox in November 1995 for $425mm) to develop devices for the endovascular market. MinTec has developed stent grafts for use in treating abdominal aortic aneurysms, peripheral aneurysms, and peripheral vascular occlusive disease.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610114http://www.elsevierbi.com/deals/199610114?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[HemaSure] (blood filtration and inactivation of pathogens in donated blood) is buying the plasma products unit (pharmaceuticals made from plasma proteins) of [Novo Nordisk] for total consideration of about $22.8mm. HemaSure will pay $1.8mm (or, at its option, about 100,000 shares of common stock) in 1988 for raw materials acquired; $13mm for inventory ($4mm of that forgivable under certain circumstances); and a 1998 contingency payment of $8mm (cash or 440,000 shares) if specified conditions are met. HemaSure plans to expand its {SteriPath} blood pathogen inactivation technology for use in the pharmaceutical sector, using the estalished manufacturing facility it is acquiring in this deal to develop {SteriPath} for the manufacture of pharmaceuticals based on plasma, a $5bn market worldwide. It hopes both to sell the products and to license the technology to other manufacturers. {SteriPath} removes leukocytes, inactivates pathogens, and then removes the inactivation chemicals. HemaSure expects to file the Investigational Device Exemption for the system later this year.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610108http://www.elsevierbi.com/deals/199610108?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)To establish a marketing presence for its recently-approved post-surgical adhesion products, [Genzyme] will acquire surgical products supplier [Deknatel Snowden Pencer] for $250mm in cash. DSP is the leading supplier of chest drainage products to the surgical market; its drainage products include {Pleur-evac} and {Thora-Klex}. The company also markets a full line of endoscopic and surgical instruments, and posted revenues of$95.3 million in 1995. Genzyme plans to close the acquisition by the end of June. It received US marketing approval for {Seprafilm}, its lead post-surgical adhesion preventing product, earlier this year and has launched it in Europe. A PMAfiled for a follow-on product, {Sepracoat}, will receive expedited FDA review.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610128http://www.elsevierbi.com/deals/199610128?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Thermo Electron] unit [ThermoTrex]'s [Trex Medical] division has bought privately-held [XRE Corp.], a manufacturer of X-ray systems for coronary artery disease diagnosis, for $17mm. XRE posted revenues of $29.3mm for 1995. Trex noted that the addition of XRE to its Lorad and Bennett X-Ray diviosions, which focus on the breast imaging and general purpose x-ray markets, adds the ability to enter the $1bn market for imaging systems used in x-ray-guided interventional cardiology procedures.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610104http://www.elsevierbi.com/deals/199610104?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Summit Technology] (ophthalmic lasers) has acquired Florida-based mail order contact lens business [Lens Express] for about $32mm in stock. Summit issued 1.7mm shares of common stock (closed on NASDAQ at $18.875 the day of the deal's announcement) to complete the transaction. Lens Express, which will operate as a division of Summit, had earnings of $2.4mm on sales of $50.6mm for the fiscal year ended June 30, 1995.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610102http://www.elsevierbi.com/deals/199610102?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[UroMed] has acquired the {Miniguard} patch, a foam pad that blocks leakage in women with mild to moderate stress incontinence, from the [Advanced Surgical Intervention Liquidating Trust] for $30mm in cash and stock. UroMed paid $7mm in cash and $23mm in stock to complete the transaction. The company noted that the acquisition complements its proprietary {Reliance} insert, another incontinence treatment product. The {Miniguard} patch was cleared by the FDA for marketing in May '96.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199610142http://www.elsevierbi.com/deals/199610142?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)Eyeglass lens manufacturer [Sola International] has definitively agreed to acquire [Neolens], a manufacturer of polycarbonate lenses, for $16mm in cash. Sola will pay $1.14 for each share of Neolens common stock (Neolens closed on the OTC Bulletin Board at $1.10 the day of the deal's announcement), $25.20 for each Series A convertible preferred share, and $41.09 for each Series B convertible preferred share. Sola and Neolens have been collaborating on the development of a polycarbonate lens product line.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620209http://www.elsevierbi.com/deals/199620209?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Boston Scientific] (interventional medical devices) and [InnerDyne] (MIS instruments) have agreed to evaluate the use of InnerDyne's biocompatible coatings with BS' implantable devices, including stents, grafts, and vena cava filters. BS will make an equity investment in InnerDyne, and will provide InnerDyne with initial research support, license fees and royalty payments should the research proceed to a technology transfer agreement. InnerDyne recently entered into its first vascular R&D agreement with [EndoTex Interventional Systems]. Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620210http://www.elsevierbi.com/deals/199620210?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[ResMed] (products to treat sleep apnea) has agreed to distribute exclusively [Compumedics]' (Australian sleep diagnostic products co.) laboratory and portable sleep diagnostic products in the US and Germany. The US and German sleep markets are the two biggest in the world, particularly in home/hospital diagnostic products and therapeutic products. The NIH-sponsored Sleep Heart Health Study is using Compumedics' products to study the cardiorespiratory consequences of mild to moderate untreated sleep apnea.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620233http://www.elsevierbi.com/deals/199620233?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[PDT] and [Iris Medical Instruments] (subsidiary of [Iridex], a maker of semiconductor-based ophthalmic laser systems) will co-develop photodynamic therapy devices for treating eye diseases. Iridex will get exclusive worldwide manufacturing and marketing rights to the light-producing devices; it will pay sales royalties to PDT. The partners' first co-developed product, a portable, solid state diode light source, is now being used in PDT's Phase I/II clinical trial of its drug SnET2 (tin ethyl etiopurpurin) for eye diseases including advanced age-related macular degeneration. About 1.2mm people in the US have AMD, which can cause blindness. After a patient receives an injection of SnET2, a low-power red light from the diode light device activates it, causing a nonthermal photochemical reaction that selectively destroys tissue in the target area. Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620245http://www.elsevierbi.com/deals/199620245?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[Baxter International Inc.]'s Vascular Systems Division has licensed exclusive rights to a minimally-invasive vascular graft system for abdominal aortic aneurysms (AAAs) from Drs. Geoffrey White and Weiyun Yu of the [University of Sydney], Australia. The new endovascular system delivers the graft to the aneurysm site via a small catheter through the femoral artery. A balloon around which the graft is wrapped inflates and affixes the graft to the aorta. Baxter's Vascular Systems Division develops and markets products used in the treatment of late-stage cardiovascular disease such as AAA, a balloon-like enlargement of the artery. Baxter is pursuing worldwide patents on the White/Yu system, which has been used in 89 patients in Australia since 1993. The system was licensed directly from its inventors and terms were not released. Baxter plans clinical trials in Australia and Europe in 1996, and in the US in 1997.Wed, 01 May 1996 00:00:00 -0400http://www.elsevierbi.com/deals/199620251http://www.elsevierbi.com/deals/199620251?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)[CompuMed] (diagnostic tests for the cardiovascular and skeletal systems) has entered into an agreement with the [University of Massachusetts] Medical Center to license technologies for performing and capturing filmless quantitative x-rays. CompuMed gets worldwide rights in the field of bone densitometry. UMMC reserves the right to license the technologies to two other companies. CompuMed will also sponsor research at UMMC for a 2-year period and will receive first option to license any new inventions arising from the research, which will focus on digital bone densitometry techniques integrating CompuMed's proprietary software. This filmless radiography may improve dose efficiency and produce higher-quality images than is possible with film. UMMC will develop the prototype filmless x-ray capture device in collaboration with CompuMed.Wed, 01 May 1996 00:00:00 -0400